Stock Scorecard
Stock Summary for Moderna Inc (MRNA) - $99.44 as of 9/27/2023 8:25:38 PM EST
Total Score
13 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for MRNA
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for MRNA
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for MRNA
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for MRNA
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for MRNA
Financial Details for MRNA
Company Overview |
|
|---|---|
| Ticker | MRNA |
| Company Name | Moderna Inc |
| Country | USA |
| Description | Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 6/30/2023 |
| Next Earnings Date | 11/1/2023 |
Stock Price History |
|
| Last Day Price | 99.44 |
| Last Day Price Updated | 9/27/2023 8:25:38 PM EST |
| Last Day Volume | 2,330,581 |
| Average Daily Volume | 4,086,474 |
| 52-Week High | 217.25 |
| 52-Week Low | 95.02 |
| Last Price to 52 Week Low | 4.65 % |
Valuation Measures |
|
| Trailing PE | 36.90 |
| Industry PE | 28.65 |
| Sector PE | 48.16 |
| 5-Year Average PE | -16.78 |
| Free Cash Flow Ratio | 4.47 |
| Industry Free Cash Flow Ratio | 14.70 |
| Sector Free Cash Flow Ratio | 32.08 |
| Current Ratio Most Recent Quarter | 3.39 |
| Total Cash Per Share | 22.23 |
| Book Value Per Share Most Recent Quarter | 44.49 |
| Price to Book Ratio | 4.46 |
| Industry Price to Book Ratio | 24.35 |
| Sector Price to Book Ratio | 21.87 |
| Price to Sales Ratio Twelve Trailing Months | 3.72 |
| Industry Price to Sales Ratio Twelve Trailing Months | 4.63 |
| Sector Price to Sales Ratio Twelve Trailing Months | 3.73 |
Share Statistics |
|
| Total Shares Outstanding | 380,593,000 |
| Market Capitalization | 37,846,167,920 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00 % |
| 5-Year Dividend Payments Count | 0 |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -97.80 % |
| Annual Earnings Growth | -31.47 % |
| Reported EPS 12 Trailing Months | 2.71 |
| Reported EPS Past Year | -3.43 |
| Reported EPS Prior Year | 19.96 |
| Net Income Twelve Trailing Months | 1,207,000,000 |
| Net Income Past Year | 8,362,000,000 |
| Net Income Prior Year | 12,202,000,000 |
| Quarterly Revenue Growth YOY | -92.80 % |
| 5-Year Revenue Growth | 245.58 % |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 8,459,000,000 |
| Total Cash Past Year | 9,902,000,000 |
| Total Cash Prior Year | 10,727,000,000 |
| Net Cash Position Most Recent Quarter | 8,459,000,000 |
| Net Cash Position Past Year | 9,902,000,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 19,123,000,000 |
| Total Stockholder Equity Prior Year | 14,145,000,000 |
| Total Stockholder Equity Most Recent Quarter | 16,949,000,000 |
Options |
|
| Put/Call Ratio | 1.88 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -1.48 |
| MACD Signal | -0.84 |
| 20-Day Bollinger Lower Band | 98.47 |
| 20-Day Bollinger Middle Band | 117.39 |
| 20-Day Bollinger Upper Band | 136.31 |
| Beta | 1.62 |
| RSI | 41.75 |
| 50-Day SMA | 145.17 |
| 200-Day SMA | 147.75 |
System |
|
| Modified | 9/26/2023 6:09:33 AM EST |